Verrica doses first US patient in pivotal Phase 3 COVE-3 trial of YCANTH for common warts

Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc.

VRCA

0.00
  • Verrica dosed the first U.S. patient in COVE-3, a pivotal Phase 3 trial of YCANTH for common warts.
  • Results have not been presented; the trial is ongoing, with COVE-3 enrolling in the U.S. and Japan.
  • The program aims to support U.S. and Japan marketing filings; YCANTH could become the first approved U.S. treatment for common warts.
  • Phase 3 initiation followed earlier Phase 2 data that showed wart clearance in a meaningful share of treated patients, with expected local skin reactions.
  • Torii will split global Phase 3 costs 50/50, funding the first $40 million, about 90% of the current trial budget.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220805PRIMZONEFULLFEED9749930) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.